BRIDGEWATER, N.J. and BENGALURU, India, Feb. 24, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...

SEOUL, South Korea--(BUSINESS WIRE)--Dong-A ST (President and CEO: Min-young Kim) (KRX:170900) announced on January 16th that therapeutic equivalence and safety were established between DMB-3115 and ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The market access agreements from numerous plans represent more ...

(Reuters) - Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor ...

Janssen's Stelara (ustekinumab) induced clinical response and clinical remission in adults with moderate to severe Crohn's disease, who had failed or were intolerant to one or more anti-TNF drugs, ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP Pharma”), a Canadian ...

Stelara is a biologic medicine used to treat moderate to severe Crohn’s disease and ulcerative colitis. Crohn’s disease and ulcerative colitis are inflammatory bowel diseases that cause inflammation ...

Johnson & Johnson recently launched Stelara for the treatment of adult patients with moderate to severe plaque psoriasis. Although Stelara is entering a crowded treatment room for psoriasis, this ...

Stelara (ustekinumab) and Humira (adalimumab) are prescription drugs used to treat certain autoimmune or inflammatory conditions. Both are injectable biologic medications. This article explains the ...

Stelara has no known food interactions, but diet is still an important part of symptom management for the conditions the drug treats. While Stelara doesn’t interact with any foods, certain foods may ...

JamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. The currently approved presentations of JamtekiTM are a 45mg/0.5mL pre-filled ...